Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder

• Editas Medicine Inc (NASDAQ: EDIT) announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine.

• EDIT-101 is under development for the treatment of blindness due to Leber congenital amaurosis 10 (LCA10, a CEP290-related retinal degenerative disorder).

• It is designed to repair the IVS26 CEP290 mutant allele that impacts approximately 1,500 LCA10 patients in the U.S.

• The BRILLIANCE update includes safety and efficacy data from all 14 patients treated in the study to date.

• Three out of 14 treated subjects experienced clinically meaningful improvements in best corrected visual acuity (BCVA) and demonstrated consistent improvements in two of the following three additional endpoints: full field sensitivity test (FST), visual function navigation course (VFN), or the visual function quality of life (VFQ).

• EDIT-101 was tolerated, with no ocular serious adverse events or dose-limiting toxicities observed.

• Given the small population (around 300 in the U.S.), the company will pause enrollment in the BRILLIANCE trial and seek to identify a collaboration partner to continue the development of EDIT-101.

• Editas Medicine will continue long-term follow-up of all patients.

• Price Action: EDIT shares are down 12% at $10.78 on the last check Thursday.

See more from Benzinga

• CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron

• Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy

• Snoop Dogg Microwaves His Blunts Before Smoking And For Good Reason, Here's Why - Raytheon Technologies (

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.